If you are looking to bolster your portfolio with some ASX 200 blue chip shares, you may want to look at the two listed below that experts rate highly.
Hereâs why analysts think they are in the buy zone this month:
Cochlear Limited (ASX: COH)
The first ASX 200 blue chip share that has been named as a buy is this leading hearing solutions company.
Goldman believes that Cochlear is well-placed to deliver the top end of its guidance this year. It commented:
In our view, the backdrop for this year appears relatively more favourable, and we see clear scope for COH to deliver at the upper-end of another solid guidance (+8-13% to $290-305m, with further accretion possible from the Oticon Medical transaction, which is yet to close).
Goldman Sachs currently has a buy rating and $247.00 price target on its shares.
Qantas Airways Limited (ASX: QAN)
Another ASX 200 blue chip share that has been named as a buy is airline operator Qantas.
Morgans is bullish on the company and believes it is well-placed in the current environment. It said:
QAN is now our preferred pick out of our travel stocks under coverage given it has the most near-term earnings momentum. Looking across travel companies globally, airlines are now in the sweet spot given demand is massively exceeding supply.
The broker also sees plenty of value in the Qantas share price at the current level. Morgans adds:
QAN is trading at a material discount compared to pre-COVID multiples, despite having structurally higher earnings, a much stronger balance sheet, a better domestic market position, a higher returning International business and more diversification (stronger Loyalty/Freight earnings).
All in all, this makes Qantas the broker’s top pick in the travel sector right now. As a result, it has put an add rating and $8.50 price target on the company’s shares.
The post Why experts say these ASX 200 blue chip shares are buys appeared first on The Motley Fool Australia.
FREE Investing Guide for Beginners
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of February 1 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 10 ASX stocks to buy before they report this earnings season: Goldman
- Virgin IPO talks are heating up. So why is the Qantas share price still climbing?
- Up 25% in a year, is it time to cash in Qantas shares?
- Should I buy Qantas shares before the company’s ASX earnings update?
- Morgans names 2 of the best ASX 200 shares to buy in February
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/LQqG6um